EUCTR2011-002872-17-IT进行中（未招募）1 期
Multicenter 3-arm trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymus -LUNA Trial
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 124
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histological confirmed advanced well differentiated carcinoma of the lung and thymus
- •Patients of all treatment lines can be included
- •At least one measurable lesion of disease on CT scan or MRI
- •Radiological documentation of disease progression within 12 months prior to randomization
- •Adequate liver, renal and bone marrow function
- •WHO Performance Status 0-2
- •Other protocol-defined inclusion criteria may apply
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 78
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 42
排除标准
- •Poorly differentiated neuroendocrine carcinoma
- •Non-neuroendocrine thymoma
- •Patients with severe functional disease requiring symptomatic treatment with somatostatin analogs
- •Prior therapy with mTOR inhibitors
- •History of liver disease
- •Baseline QTcF> 470 msec
- •Uncontrolled diabetes mellitus despite adequate therapy
- •Other protocol-defined exclusion criteria may apply
研究者
相似试验
进行中（未招募）
不适用
Clinical trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymusEUCTR2011-002872-17-DKovartis Pharma Services AG124
进行中（未招募）
1 期
Clinical trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymusEUCTR2011-002872-17-DEovartis Pharma Services AG124
进行中（未招募）
1 期
Clinical trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymusEUCTR2011-002872-17-ESovartis Farmacéutica S.A.105
进行中（未招募）
1 期
Clinical trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymusEUCTR2011-002872-17-SEovartis Pharma Services AG124
进行中（未招募）
1 期
Clinical trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymuseouroendocrine carcinoma of the lung and thymusMedDRA version: 20.0Level: LLTClassification code 10025064Term: Lung carcinomaSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10062476Term: Neuroendocrine tumorSystem Organ Class: 100000004864EUCTR2011-002872-17-GBovartis Pharma Services AG124